244 related articles for article (PubMed ID: 27941058)
1. Acute effects of the glucagon-like peptide-1 receptor agonist, exenatide, on blood pressure and heart rate responses to intraduodenal glucose infusion in type 2 diabetes.
Thazhath SS; Marathe CS; Wu T; Chang J; Khoo J; Kuo P; Checklin HL; Bound MJ; Rigda RS; Horowitz M; Jones KL; Rayner CK
Diab Vasc Dis Res; 2017 Jan; 14(1):59-63. PubMed ID: 27941058
[TBL] [Abstract][Full Text] [Related]
2. The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial.
Thazhath SS; Marathe CS; Wu T; Chang J; Khoo J; Kuo P; Checklin HL; Bound MJ; Rigda RS; Crouch B; Jones KL; Horowitz M; Rayner CK
Diabetes; 2016 Jan; 65(1):269-75. PubMed ID: 26470783
[TBL] [Abstract][Full Text] [Related]
3. Effects of sitagliptin on blood pressure and heart rate in response to intraduodenal glucose infusion in patients with Type 2 diabetes: a potential role for glucose-dependent insulinotropic polypeptide?
Wu T; Trahair LG; Bound MJ; Deacon CF; Horowitz M; Rayner CK; Jones KL
Diabet Med; 2015 May; 32(5):595-600. PubMed ID: 25388434
[TBL] [Abstract][Full Text] [Related]
4. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
DeFronzo RA; Okerson T; Viswanathan P; Guan X; Holcombe JH; MacConell L
Curr Med Res Opin; 2008 Oct; 24(10):2943-52. PubMed ID: 18786299
[TBL] [Abstract][Full Text] [Related]
5. GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Serné EH; van Raalte DH
Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2125-32. PubMed ID: 27562916
[TBL] [Abstract][Full Text] [Related]
6. Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.
Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; van Raalte DH
Eur J Endocrinol; 2017 Jan; 176(1):77-86. PubMed ID: 27777261
[TBL] [Abstract][Full Text] [Related]
7. Impact of the timing of metformin administration on glycaemic and glucagon-like peptide-1 responses to intraduodenal glucose infusion in type 2 diabetes: a double-blind, randomised, placebo-controlled, crossover study.
Xie C; Iroga P; Bound MJ; Grivell J; Huang W; Jones KL; Horowitz M; Rayner CK; Wu T
Diabetologia; 2024 Jul; 67(7):1260-1270. PubMed ID: 38561463
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.
Malloy J; Capparelli E; Gottschalk M; Guan X; Kothare P; Fineman M
Clin Ther; 2009 Apr; 31(4):806-15. PubMed ID: 19446153
[TBL] [Abstract][Full Text] [Related]
9. Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men.
Muskiet MH; Tonneijck L; Smits MM; Kramer MH; Diamant M; Joles JA; van Raalte DH
Diabetes Obes Metab; 2016 Feb; 18(2):178-85. PubMed ID: 26636423
[TBL] [Abstract][Full Text] [Related]
10. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
Linnebjerg H; Kothare PA; Skrivanek Z; de la Peña A; Atkins M; Ernest CS; Trautmann ME
Diabet Med; 2006 Mar; 23(3):240-5. PubMed ID: 16492205
[TBL] [Abstract][Full Text] [Related]
11. Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.
Simó R; Guerci B; Schernthaner G; Gallwitz B; Rosas-Guzmàn J; Dotta F; Festa A; Zhou M; Kiljański J
Cardiovasc Diabetol; 2015 Sep; 14():116. PubMed ID: 26338040
[TBL] [Abstract][Full Text] [Related]
12. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.
Tonneijck L; Smits MM; Muskiet MHA; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
Diabetologia; 2016 Jul; 59(7):1412-1421. PubMed ID: 27038451
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial.
Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Diamant M; Pieters-van den Bos IC; van Raalte DH; Cahen DL
Diabetes Obes Metab; 2016 Mar; 18(3):281-8. PubMed ID: 26640129
[TBL] [Abstract][Full Text] [Related]
14. Effects of intraduodenal hydroxycitrate on glucose absorption, incretin release, and glycemia in response to intraduodenal glucose infusion in health and type 2 diabetes: A randomised controlled trial.
Thazhath SS; Wu T; Bound MJ; Checklin HL; Standfield S; Jones KL; Horowitz M; Rayner CK
Nutrition; 2016 May; 32(5):553-9. PubMed ID: 26792024
[TBL] [Abstract][Full Text] [Related]
15. Effect of continuous exenatide infusion on cardiac function and peri-operative glucose control in patients undergoing cardiac surgery: A single-blind, randomized controlled trial.
Lipš M; Mráz M; Kloučková J; Kopecký P; Dobiáš M; Křížová J; Lindner J; Diamant M; Haluzík M
Diabetes Obes Metab; 2017 Dec; 19(12):1818-1822. PubMed ID: 28581209
[TBL] [Abstract][Full Text] [Related]
16. A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes.
Henry RR; Logan D; Alessi T; Baron MA
Clin Ther; 2013 May; 35(5):634-645.e1. PubMed ID: 23578605
[TBL] [Abstract][Full Text] [Related]
17. The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients.
Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; van Raalte DH
Diabetes Res Clin Pract; 2017 Feb; 124():1-10. PubMed ID: 28086201
[TBL] [Abstract][Full Text] [Related]
18. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.
Schwartz EA; Koska J; Mullin MP; Syoufi I; Schwenke DC; Reaven PD
Atherosclerosis; 2010 Sep; 212(1):217-22. PubMed ID: 20557887
[TBL] [Abstract][Full Text] [Related]
19. Effects of physiological hyperglycemia on duodenal motility and flow events, glucose absorption, and incretin secretion in healthy humans.
Kuo P; Wishart JM; Bellon M; Smout AJ; Holloway RH; Fraser RJ; Horowitz M; Jones KL; Rayner CK
J Clin Endocrinol Metab; 2010 Aug; 95(8):3893-900. PubMed ID: 20501683
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans.
van Raalte DH; van Genugten RE; Linssen MM; Ouwens DM; Diamant M
Diabetes Care; 2011 Feb; 34(2):412-7. PubMed ID: 21216851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
